Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

So continues the rocky path for the drug, which Sanofi picked up in its $3.7 billion buyout of Principia Biopharma back in ...

Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia ...

Sanofi sees continued growth and strong financials despite a pipeline setback. Click for this updated look at SNY stock ...

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

The PERSEUS trial was a global, double-blind, randomized Phase 3 study comparing tolebrutinib to placebo in PPMS patients.

Tolebrutinib is currently being reviewed by the Food and Drug Administration (FDA) for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS). A regulatory decision on the ...

A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to ...

French pharmaceutical group Sanofi said on Monday the U.S. Food and Drug Administration's decision on its investigative drug ...

French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...